Antibiotic Awareness Week – What the UN says about taking action against resistance

As the global concern over antibiotic resistance grows, more and more world organizations are weighing in on the need for action in the fight against resistance. This Antibiotic Awareness Week, we’re highlighting some of the key points addressed by the UN General Assembly at their High Level Meeting on AMR held earlier this fall.  On September 21, 2016 in New …

[E-Book] Global Health Organizations Getting the Word Out About Resistance

It’s World Antibiotic Awareness Week, a global awareness campaign dedicated to making sure the world stays educated on the causes of antibiotic resistance and what can be done to prevent it before it even happens! Championed by WHO and other global health organizations, Antibiotic Awareness Week uses social media campaigns, webinars, independent events, and more to get the word out …

[WHITEPAPER] MDRO Trends Throughout Intermountain Healthcare System

 MDRO Trends Throughout Intermountain Healthcare System  courtesy of OpGen This whitepaper discusses a study conducted by Intermountain Healthcare System and Enterprise Analysis Corporation (EAC) with support from OpGen that examined the trends in MDROs (multidrug resistant organisms) over the 8 year period of 2008-2015. The paper discusses the objectives of the study, which was initiated in December 2015 and concluded …

Steven Gilman of Contrafect Corporation: Featured Speaker of World Anti-Microbial Resistance Congress

Steven Gilman of Contrafect Corporation: Featured Speaker at World Anti-Microbial Resistance Congress USA 2016

Dr. Gilman most recently served as the Executive Vice President, Research & Development and Chief Scientific Officer at Cubist Pharmaceuticals until its acquisition by Merck & Co. Prior to joining Cubist in 2008, Dr. Gilman served as Chairman of the Board of Directors and Chief Executive Officer of ActivBiotics, a privately held biopharmaceutical company. Previously, Dr. Gilman worked at Millennium …

[WHITEPAPER] Quantitative Urine Culture in cUTI Trials: What is the Problem with Genomix? Part 2

Quantitative Urine Culture in cUTI Trials: What is the Problem With Genomix? Part 2 Courtesy of PSI CRO A continuation of an earlier article by the same name, this article builds upon the first, which discussed the challenges and best practices involved in achieving the ideal outcomes when performing quantitative urine culture studies. The second installment goes on to discuss …

[WHITEPAPER] Quantitative Urine Culture in cUTI Trials: What is the Problem With Genomix? Part 1

Quanitative Urine Culture in cUTI Trials: What is the Problem With Genomix? Part 1 courtesy of PSI CRO The first in a two-part article, this whitepaper discusses the challenges and best practices involved in achieving ideal outcomes in quantitative urine culture studies. Download the whitepaper now to learn more about: urine specimen stability quantitative urine culture contamination rates …and more ! …

David Mantus: Featured Speaker at World Anti-Microbial Resistance Congress USA 2016

David Mantus of Arsanis: Featured Speaker at World Anti-Microbial Resistance Congress USA 2016

David Mantus, Ph.D. is Chief Development Officer at Arsanis, Inc., a clinical stage biotechnology company developing monoclonal antibodies to prevent and treat serious bacterial infections. He has more than 24 years of drug development experience, including clinical, regulatory and manufacturing successes for programs in endocrinology, central nervous disorders, and infectious disease. His work in infectious disease product development has included …

Sumathi Nambiar of FDA: Featured Speaker at World Anti-Microbial Resistance Congress USA 2016

Dr. Sumathi Nambiar is Director of the Division of Anti-Infective Products, Office of Antimicrobial Products, since July 2013. Dr. Nambiar joined the Division of Anti-Infective Products in 2002. In her current role, Dr. Nambiar provides regulatory oversight for anti-infective products, including antibacterial, antifungal, and antiparasitic drugs. Dr. Nambiar is board-certified in pediatrics and pediatric infectious diseases. She completed her pediatric …

[WHITEPAPER] Rapid Molecular Diagnostics: Supporting CDC’s Four Core Actions to Fight Antimicrobial Resistance

Rapid Molecular Diagnostics: Supporting CDC’s Four Core Actions to Fight Antimicrobial Resistance Download the whitepaper, courtesy of Cepheid here>> Some of the most widely used therapies in medicine, antibiotics have also steadily become some of the most improperly used treatments. Antibiotics have saved many lives and changed the face of medicine, but reliance upon them has also led to serious …

Judy Hackett of AstraZeneca: Featured Speaker at World Anti-Microbial Resistance Congress USA 2016

Judy Hackett received her Pharmacy Degree from the University of Toronto.  She subsequently completed her M.B.A. at York University.  As well she has a graduate degree in Evaluation and Outcomes from the Faculty of Medicine,  University of Toronto. She began her career working in community pharmacy and then went onto work as a payer where she developed and managed drug …